Dysregulation of C/EBPα by mutant Huntingtin causes the urea cycle deficiency in Huntington's disease
The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by a CAG trinucleotide expansion in the Huntingtin (Htt) gene. Using two mouse models of HD, we demonstrate that the urea cycle deficiency characterized by hyperammonemia, high blood citrulline and suppression of urea cycle enzymes is a prominent feature of HD. The resultant ammonia toxicity might exacerbate the neurological deficits of HD. Suppression of C/EBPalpha, a crucial transcription factor for the transcription of urea cycle enzymes, appears to mediate the urea cycle deficiency in HD. We found that in the presence of mutant Htt, C/EBPalpha loses its ability to interact with an important cofactor (CREB-binding protein). Moreover, mutant Htt recruited C/EBPalpha into aggregates, as well as suppressed expression of the C/EBPalpha gene. Consumption of protein-restricted diets not only led to the restoration of C/EBPalpha's activity, and repair of the urea cycle deficiency and hyperammonemia, but also ameliorated the formation of Htt aggregates, the motor deterioration, the suppression of striatal brain-derived neurotrophic factor and the normalization of three protein chaperones (Hsp27, Hsp70 and Hsp90). Treatments aimed at repairing the urea cycle deficiency may provide a new strategy for dealing with HD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, deficits in toxin clearance in aged livers increase the concentrations of circulating toxic substances, especially citrulline and ammonia, which may accelerate the onset of HD.232”
From Antiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances (2025) · cites this paper as [232]
Citations
Cites
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062
Wu, Z., Rosen, E. D., Brun, R., Hauser, S., Adelmant, G., Troy, A. E., McKeon, C., Darlington, G. J., & Spiegelman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80306-8 · Cited by 1,015
Impaired Energy Homeostasis in C/EBPα Knockout Mice
Wang, N.-D., Finegold, M. J., Bradley, A., Ou, C. N., Abdelsayed, S. V., Wilde, M. D., Taylor, L. R., Wilson, D. R., & Darlington, G. J. (1995) · Science · doi:10.1126/science.7652557 · Cited by 929
Differential loss of striatal projection neurons in Huntington disease.
Reiner, A., Albin, R. L., Anderson, K. D., D'Amato, C. J., Penney, J. B., & Young, A. B. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.15.5733 · Cited by 839
Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease
Tanaka, M., Machida, Y., Niu, S., Ikeda, T., Jana, N. R., Doi, H., Kurosawa, M., Nekooki, M., & Nukina, N. (2004) · Nature Medicine · doi:10.1038/nm985 · Cited by 782
Cited by
Manganese Is Essential for Neuronal Health
Horning, K. J., Caito, S. W., Tipps, K. G., Bowman, A. B., & Aschner, M. (2015) · Annual Review of Nutrition · doi:10.1146/annurev-nutr-071714-034419 · Cited by 602
“For example, many critical Mn-dependent enzymes of the brain show diminished levels of activity in HD patients and other models of HD (36, 44, 45).”
BackgroundTherapeutic potential of mood stabilizers lithium and valproic acid:Beyond bipolar disorder
Chiu, C.-T., Wang, Z., Hunsberger, J. G., & Chuang, D.-M. (2013) · Pharmacological Reviews · doi:10.1124/pr.111.005512 · Cited by 404
Role of manganese in neurodegenerative diseases
Bowman, A. B., Kwakye, G. F., Herrero Hernández, E., & Aschner, M. (2011) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2011.08.144 · Cited by 395
Beyond the brain: widespread pathology in Huntington's disease
van der Burg, J. M., Björkqvist, M., & Brundin, P. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70178-4 · Cited by 363
Hsiao, H.-Y., Chen, Y.-C., Chen, H.-M., Tu, P.-H., & Chern, Y. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt036 · Cited by 239
Self-citationTreating the whole body in Huntington's disease
Carroll, J. B., Bates, G. P., Steffan, J. S., Saft, C., & Tabrizi, S. J. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00177-5 · Cited by 194
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington’s Disease Research
Jiang, A., Handley, R. R., Lehnert, K., & Snell, R. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241613021 · Cited by 191
Nuclear translocation of AMPK-α1 potentiates striatal neurodegeneration in Huntington’s disease
Ju, T.-C., Chen, H.-M., Lin, J.-T., Chang, C.-P., Chang, W.-C., Kang, J.-J., Sun, C.-P., Tao, M.-H., Tu, P.-H., Chang, C., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201105010 · Cited by 183
Self-citationThe Glutamate/ GABA ‐Glutamine Cycle: Insights, Updates, and Advances
Andersen, J. V. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70029 · Cited by 182
“Elevated brain ammonia levels have also been reported in Alzheimer's disease and Huntington's disease (Seiler 2002; Chiang et al. 2007).”
Andersen, J. V., & Schousboe, A. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15811 · Cited by 170
Shen, W.-C., Li, H.-Y., Chen, G.-C., Chern, Y., & Tu, P.-H. (2015) · Autophagy · doi:10.4161/auto.36098 · Cited by 169
Self-citationAntiageing strategy for neurodegenerative diseases: from mechanisms to clinical advances
Jiang, Q., Liu, J., Huang, S., Wang, X.-Y., Chen, X., Liu, G.-H., Ye, K., Song, W., Masters, C. L., Wang, J., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02145-7 · Cited by 165
Chiu, C., Liu, G., Leeds, P. R., & Chuang, D. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.128 · Cited by 155
“In addition, HSP70 and its cochaperone HSP40 were found to colocalize with huntingtin aggregates (Jana et al, 2000) and were decreased in the brains of HD animal models (Chiang et al, 2007; Duan et al, 2008; Hay et al, 2004; Yamanaka et al, 2008).”
BackgroundInhibition of soluble tumor necrosis factor is therapeutic in Huntington's disease
Hsiao, H.-Y., Chiu, F.-L., Chen, C.-M., Wu, Y.-R., Chen, H.-M., Chen, Y.-C., Kuo, H.-C., & Chern, Y. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu151 · Cited by 134
Self-citationPPARgamma rescue of the mitochondrial dysfunction in Huntington's disease
Chiang, M.-C., Chern, Y., & Huang, R.-N. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.08.016 · Cited by 97
“…studies suggests that mHtt forms aggregates and causes aberrant protein-protein interactions with a number of important transcription factors or coactivators, such as p53, CREB, CBP, SP1, TAFII130, and 14-3-3 zeta (Chiang et al., 2005, 2007a, 2007b; Dunah et al., 2002; Steffan et al., 2000).”
Self-citationChou, S.-Y., Weng, J.-Y., Lai, H.-L., Liao, F., Sun, S. H., Tu, P.-H., Dickson, D. W., & Chern, Y. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.0116-08.2008 · Cited by 115
“In addition to neurons, mHtt has also been found in many different types of cells, including glial cells in the brain, muscle cells, and liver hepatocytes (Orth et al., 2003; Shin et al., 2005; Chiang et al., 2007).”
BackgroundSelf-citationGastrointestinal dysfunction contributes to weight loss in Huntington's disease mice
van der Burg, J. M. M., Winqvist, A., Aziz, N. A., Maat-Schieman, M. L. C., Roos, R. A. C., Bates, G. P., Brundin, P., Björkqvist, M., & Wierup, N. (2011) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.05.006 · Cited by 110
“Studies in other parts of the body, especially the brain, have shown that mutant huntingtin could cause transcriptional down-regulation of many proteins (Chiang et al., 2007; Chiang et al., 2010; Hodges et al., 2006; Luthi-Carter et al., 2002) that may be essential for survival and appropriate functioning of cells.”
BackgroundHandley, R. R., Reid, S. J., Bräuning, R., Maclean, P. H., Mears, E., Fourie, I., Patassini, S., Cooper, G. J. S., Rudiger, S. R., McLaughlan, C. J., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1711243115 · Cited by 110
Relationships Between Essential Manganese Biology and Manganese Toxicity in Neurological Disease
Pfalzer, A. C., & Bowman, A. B. (2017) · Current Environmental Health Reports · doi:10.1007/s40572-017-0136-1 · Cited by 106
Chiang, M.-C., Chen, C.-M., Lee, M.-R., Chen, H.-W., Chen, H.-M., Wu, Y.-S., Hung, C.-H., Kang, J.-J., Chang, C.-P., Chang, C., et al. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq322 · Cited by 96
Self-citationGlial Glutamine Homeostasis in Health and Disease
Andersen, J. V., & Schousboe, A. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03771-1 · Cited by 101
Chen, C. (2011) · PubMed · Cited by 97
Self-citationChen, J., & Chern, Y. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_10 · Cited by 92
Self-citationA New Drug Design Targeting the Adenosinergic System for Huntington's Disease
Huang, N.-K., Lin, J.-H., Lin, J.-T., Lin, C.-I., Liu, E. M., Lin, C.-J., Chen, W.-P., Shen, Y.-C., Chen, H.-M., Chen, J.-B., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020934 · Cited by 82
“Formation of Htt aggregates and alteration of overall gene expression profiles have also been reported in peripheral tissues, including blood cells, the liver, and the kidney [2,3].”
Self-citationMastrokolias, A., Ariyürek, Y., Goeman, J. J., van Duijn, E., Roos, R. A. C., van der Mast, R. C., van Ommen, G. B., den Dunnen, J. T., Hoen, P. A. C. ’., & van Roon‐Mom, W. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2014.281 · Cited by 90
Ehrnhoefer, D. E., Martin, D. D. O., Schmidt, M. E., Qiu, X., Ladha, S., Caron, N. S., Skotte, N. H., Nguyen, Y. T. N., Vaid, K., Southwell, A. L., et al. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0518-0 · Cited by 82
Chiang, M.-C., Chen, H.-M., Lai, H.-L., Chen, H.-W., Chou, S.-Y., Chen, C.-M., Tsai, F.-J., & Chern, Y. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp230 · Cited by 83
Self-citationMetabolic profiling of presymptomatic Huntington’s disease sheep reveals novel biomarkers
Skene, D. J., Middleton, B., Fraser, C. K., Pennings, J. L. A., Kuchel, T. R., Rudiger, S. R., Bawden, C. S., & Morton, A. J. (2017) · Scientific Reports · doi:10.1038/srep43030 · Cited by 85
Chen, K.-P., Hua, K., Tsai, F.-T., Lin, T.-Y., Cheng, C., Yang, D., Hsu, H.-T., & Ju, T. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-022-02419-9 · Cited by 81
Patassini, S., Begley, P., Reid, S. J., Xu, J., Church, S. J., Curtis, M. A., Dragunow, M., Waldvogel, H. J., Unwin, R. D., Snell, R. G., et al. (2015) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2015.10.140 · Cited by 75
Towards an Understanding of Energy Impairment in Huntington’s Disease Brain
Dubinsky, J. M. (2017) · Journal of Huntington s Disease · doi:10.3233/jhd-170264 · Cited by 72
Systemic manifestation and contribution of peripheral tissues to Huntington’s disease pathogenesis
Chuang, C.-L., & Demontis, F. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101358 · Cited by 64
Tidball, A. M., Bryan, M. R., Uhouse, M. A., Kumar, K. K., Aboud, A. A., Feist, J. E., Ess, K. C., Neely, M. D., Aschner, M., & Bowman, A. B. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu609 · Cited by 70
Ornithine Transcarbamylase – From Structure to Metabolism: An Update
Couchet, M., Breuillard, C., Corne, C., Rendu, J., Morio, B., Schlattner, U., & Moinard, C. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.748249 · Cited by 66
Williams, B. B., Kwakye, G. F., Węgrzynowicz, M., Li, D. D., Aschner, M., Erikson, K. M., & Bowman, A. B. (2010) · Toxicological Sciences · doi:10.1093/toxsci/kfq174 · Cited by 63
“Finally, the Mn-dependent enzyme arginase regulates the final step of the urea cycle in liver; both HD patients and mouse models have deficiencies in the urea cycle (Chiang et al., 2007; Stoy et al., 2005).”
BackgroundBehavioural and expressional phenotyping of nitric oxide synthase-I knockdown animals
Wultsch, T., Chourbaji, S., Fritzen, S., Kittel, S., Grünblatt, E., Gerlach, M., Gutknecht, L., Chizat, F., Golfler, G., Schmitt, A. G., et al. (2007) · Springer eBooks · doi:10.1007/978-3-211-73574-9_10 · Cited by 61
Patassini, S., Begley, P., Xu, J., Church, S. J., Reid, S. J., Kim, E. H., Curtis, M. A., Dragunow, M., Waldvogel, H. J., Snell, R. G., et al. (2016) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2016.06.002 · Cited by 59
A Critical Evaluation of Wet Biomarkers for Huntington’s Disease: Current Status and Ways Forward
Silajdžić, E., & Björkqvist, M. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-170273 · Cited by 57
“24OHC ↓ TMS [65, 66] [59, 65, 66] Cognition [66] Striatal volume [66] Caudate volume [59] 5-HT ↑ [275] ↓ [55, 107] = [43] ApoA4, CSF ↑ [117, 276] Arginine ↑ [57, 58] = [38, 47, 55–57] Cholesterol, total ↓ Psychosis [277] [34, 65, 277] = Cognition [278] [57, 59–64, 102, 106, 278, 279] Citrulline ↑ Duration [280] [280,…”
Mass Spectrometric Identification of Novel Lysine Acetylation Sites in Huntingtin
Cong, X., Held, J. M., DeGiacomo, F., Bonner, A., Chen, J. M., Schilling, B., Czerwieniec, G. A., Gibson, B. W., & Ellerby, L. (2011) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m111.009829 · Cited by 57
Targeting Glial Cells to Elucidate the Pathogenesis of Huntington’s Disease
Hsiao, H., & Chern, Y. (2010) · Molecular Neurobiology · doi:10.1007/s12035-009-8097-5 · Cited by 52
Self-citationChiang, M., Cheng, Y., Nicol, C. J. B., Lin, K., Yen, C., Chen, S., & Huang, R. (2015) · Experimental Cell Research · doi:10.1016/j.yexcr.2015.09.005 · Cited by 47
Self-citationThe dysfunction of hepatic transcriptional factors in mice with Huntington's Disease
Chiang, M., Chern, Y., & Juo, C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.05.006 · Cited by 46
Self-citationLin, Y.-S., Cheng, T.-H., Chang, C.-P., Chen, H., & Chern, Y. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2013.02.006 · Cited by 44
“A filter retardation assay was performed as described previously [22,38].”
MethodSelf-citationRestricted Transgene Expression in the Brain with Cell-Type Specific Neuronal Promoters
Delzor, A., Dufour, N., Petit, F., Guillermier, M., Houitte, D., Aurégan, G., Brouillet, E., Hantraye, P., & Déglon, N. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.073 · Cited by 45
“…a protein altering the function of several transcription factors and regulators, including Sp1, TBP, CREB, and REST (Steffan et al., 2000; Li et al., 2002; Chiang et al., 2007; Ravache et al., 2010), Dlx5/6 transcriptional activity was lower than in animals expressing a wildtype Htt fragment.”
BackgroundMcGarry, A. J., Gaughan, J., Hackmyer, C., Lovett, J., Khadeer, M., Shaikh, H. A., Pradhan, B., Ferraro, T. N., Wainer, I. W., & Moaddel, R. (2020) · Scientific Reports · doi:10.1038/s41598-020-77526-9 · Cited by 43
Perdoncin, M., Konrad, A., Wyner, J. R., Lohana, S., Pillai, S. S., Pereira, D. G., Lakhani, H. V., & Sodhi, K. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.756499 · Cited by 40
Energy dysfunction in Huntington’s disease: insights from PGC-1α, AMPK, and CKB
Ju, T., Lin, Y., & Chern, Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1025-2 · Cited by 40
“d if fi cu lt ie s, an d h ea ri n g im p ai rm en t [6 , 1 5 7 , 1 5 9 , 1 8 9 , 1 9 0 ]”
BackgroundInfluentialSelf-citationReduced gluconeogenesis and lactate clearance in Huntington's disease
Josefsen, K. E., Nielsen, S. M. B., Campos, A., Seifert, T., Hasholt, L., Nielsen, J. E., Nørremølle, A., Skotte, N. H., Secher, N. H., & Quistorff, B. (2010) · Neurobiology of Disease · doi:10.1016/j.nbd.2010.08.009 · Cited by 39
Metabolism in Huntington’s disease: a major contributor to pathology
Singh, A., & Agrawal, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00844-y · Cited by 35
Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington’s disease
Niu, L., Ye, C., Sun, Y. T., Peng, T., Yang, S., Wang, W., & He, L. (2018) · Cell & Bioscience · doi:10.1186/s13578-018-0239-x · Cited by 33
Transgenic Animal Models of Huntington’s Disease
Yang, S., & Chan, A. W. S. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_105 · Cited by 30
Courtes, A. A., Arantes, L. P., Barcelos, R. P., da Silva, I. K., Boligon, A. A., Athayde, M. L., Puntel, R. L., & Soares, F. A. A. (2015) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2015/723431 · Cited by 30
Hernández, I. H., Torres-Peraza, J. F., Santos‐Galindo, M., Ramos-Morón, E., Fernández-Fernández, M. R., Pérez-Álvarez, M. J., Miranda‐Vizuete, A., & Lucas, J. J. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1770-2 · Cited by 28
Lakra, P., Aditi, K., & Agrawal, N. (2019) · Scientific Reports · doi:10.1038/s41598-019-46470-8 · Cited by 28
Gómez-Jaramillo, L., Cano-Cano, F., González-Montelongo, M. D. C., Campos‐Caro, A., Aguilar‐Diosdado, M., & Arroba, A. I. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116089 · Cited by 25
“Both R6/2 and HdhQ150 knock-in mice showed deficiency in the urea cycle, with hyperammonemia, high blood citrulline levels and the suppression of urea cycle enzymes as prominent features of HD [75].”
BackgroundModelling the Human Blood–Brain Barrier in Huntington Disease
Vignone, D., Paz, O. G., Fini, I., Cellucci, A., Auciello, G., Battista, M. R., Gloaguen, I., Fortuni, S., Cariulo, C., Khetarpal, V. K., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147813 · Cited by 25
Akyol, S., Ashrafi, N., Yılmaz, A., Türkoğlu, O., & Graham, S. F. (2023) · Metabolites · doi:10.3390/metabo13121203 · Cited by 25
Li, L., Sun, Y. T., Zhang, Y., Wang, W., & Ye, C. (2021) · Journal of Molecular Neuroscience · doi:10.1007/s12031-021-01869-9 · Cited by 24
Hua, K., Chao, A., Lin, T.-Y., Chen, W.-T., Lee, Y., Hsu, W., Lee, S.-L., Wang, H.-M., Yang, D., & Ju, T. (2021) · Journal of Ginseng Research · doi:10.1016/j.jgr.2021.11.003 · Cited by 22
Self-citationEnhanced cerebral branched-chain amino acid metabolism in R6/2 mouse model of Huntington’s disease
Andersen, J. V., Skotte, N. H., Aldana, B. I., Nørremølle, A., & Waagepetersen, H. S. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03051-2 · Cited by 22
Luo, H., Cao, L., Liang, X., Du, A., Peng, T., & He, L. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0900-8 · Cited by 22
Liver function in Huntington's disease assessed by blood biochemical analyses in a clinical setting
Nielsen, S. M. B., Vinther‐Jensen, T., Nielsen, J. E., Nørremølle, A., Hasholt, L., Hjermind, L. E., & Josefsen, K. E. (2016) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.02.018 · Cited by 20
“ALT serum activity has previously been determined to be normal in two small studies of early to midand late-stage HD-GEC respectively [33, 34] as well as in R6/2 mice [13].”
Huntington’s Disease: Clinical Features and Routes to Therapy
Paulson, H. L., & Albin, R. L. (2011) · Europe PMC (PubMed Central) · Cited by 19
Coffey, S. R., Bragg, R. M., Minnig, S., Ament, S. A., Cantle, J. P., Glickenhaus, A., Shelnut, D., Carrillo, J. M., Shuttleworth, D. D., Rodier, J.-A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0175968 · Cited by 19
Gyawali, A., Gautam, S., Hyeon, S. J., Ryu, H., & Kang, Y. (2020) · Molecular Neurobiology · doi:10.1007/s12035-020-02143-6 · Cited by 19
Inflammatory changes in peripheral organs in the BACHD murine model of Huntington's disease
Valadão, P. A. C., Oliveira, B. D. S., Joviano‐Santos, J. V., Vieira, É. L. M., Rocha, N. P., Teixeira, A. L., Guatimosim, C., & de Miranda, A. S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116653 · Cited by 18
High Protein Diet and Huntington's Disease
Chen, C., Lin, Y., Wu, Y., Tu, C. D., Tsai, F., Yang, C.-L., Tsao, Y.-T., Chang, W., Hsieh, I., Chern, Y., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127654 · Cited by 18
“Dietary intervention to provide proper nutrition to HD patients has been discussed and investigated [13,21–23,32].”
BackgroundMethodResultInfluentialSelf-citationCharacteristics, Pathophysiology and Clinical Management of Weight Loss in Huntington’s Disease
Aziz, N. A., & Roos, R. A. C. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.22 · Cited by 17
Hogel, M., Laprairie, R. B., & Denovan‐Wright, E. M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041152 · Cited by 16
“Elimination of a C/EBP binding site resulted in the recovery of transcription at the argininosuccinate acid lyase (AAL) promoter in the presence of N-mHtt [36].”
BackgroundLee, M., Chang, C., Lee, Y.-H., Wu, Y., Tseng, H., Tung, Y., Wu, M.-T., Chen, Y., Kuo, L., Stephenson, D. A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007868 · Cited by 16
“Cells were counter-stained with either an anti-NeuN antibody (1:500; Chemicon, Temecula, CA, USA) as previously described [52] or Hoechst 33342.”
MethodSelf-citationBonomo, R., Cavaletti, G., & Skene, D. J. (2020) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1782746 · Cited by 14
Huntingtin loss in hepatocytes is associated with altered metabolism, adhesion, and liver zonation
Bragg, R. M., Coffey, S. R., Cantle, J. P., Hu, S., Singh, S., Legg, S. R. W., McHugh, C. A., Toor, A., Zeitlin, S. O., Kwak, S., et al. (2023) · Life Science Alliance · doi:10.26508/lsa.202302098 · Cited by 10
A(a)LS: Ammonia-induced amyotrophic lateral sclerosis
Parekh, B. K. (2015) · F1000Research · doi:10.12688/f1000research.6364.1 · Cited by 10
Metabolomics: a new frontier in neurodegenerative disease biomarker discovery
Verma, K. K., Gaur, P. K., Gupta, S. L., Lata, K., Kaushik, R., & Sharma, V. M. (2025) · Metabolomics · doi:10.1007/s11306-025-02267-7 · Cited by 8
“Metabolomics studies in Huntington’s Disease reported reduced levels of amino acids such as tyrosine, isoleucine and valine, whereas increased level of glycine, and low phosphatidylcholine concentrations (Chiang et al., 2007; Chen et al., 2015 ; Skene et al., 2017).”
Alterations in Cerebrospinal Fluid Urea Occur in Late Manifest Huntington’s Disease
Pfalzer, A. C., Shiino, S., Silverman, J., Codreanu, S. G., Sherrod, S. D., MCLEAN, J. A. J., & Claassen, D. O. (2024) · Journal of Huntington s Disease · doi:10.3233/jhd-231511 · Cited by 8
Doença de Huntington : onde estamos agora?
Januário, C. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 8
Chang, Y., Chen, C., Chen, Y., Wu, M.-T., Lin, T.-Y., Hua, K., & Ju, T. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10161-7 · Cited by 7
“Ulti - mately, this accumulation leads to functional impairment in neuronal cells (Group 1993 ; Li et al. 2001 ; Lin et al. 2011 ; Chiang et al. 2007 ).”
Self-citationCardiac electrical remodeling and neurodegenerative diseases association
Joviano‐Santos, J. V., Santos‐Miranda, A., & Roman‐Campos, D. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118976 · Cited by 5
Iron-Calcium Crosstalk in Neurodegenerative Diseases
Kadian, M., Sharma, G., & Kumar, A. (2022) · Nutritional neurosciences · doi:10.1007/978-981-19-7327-7_6 · Cited by 5
Neuroprotective Effects of Glucosamine in Huntington’s Disease Through NLRP3 Inflammasome Inhibition
Chu, L. J., Hsu, Y.-C., Aoh, Y., Cheng, C., Wang, H., Wu, M., Li, H., Lai, X.-Y., Hua, K., Chen, C., et al. (2025) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-025-10265-8 · Cited by 4
Self-citationPolyglutamine disease in peripheral tissues
Barwell, T., & Seroude, L. (2023) · Human Molecular Genetics · doi:10.1093/hmg/ddad138 · Cited by 4
Šmatlíková, P., Juhás, Š., Juhásová, J., Suchý, T., Kalbáčová, M. H., Ellederová, Z., Motlík, J., & Klíma, J. (2018) · Journal of Huntington s Disease · doi:10.3233/jhd-180303 · Cited by 4
Metal Biology Associated with Huntington’s Disease
Bichell, T. J., Halbesma, T. C., Tipps, K. G., & Bowman, A. B. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-804562-6.00013-0 · Cited by 4
Influence of dietary patterns in the pathophysiology of Huntington's Disease: A literature review
Ansari, U., Nadora, D., Alam, M., Wen, J., Asad, S., & Lui, F. (2024) · AIMS neuroscience · doi:10.3934/neuroscience.2024005 · Cited by 3
“In mice studies, a low protein diet has been shown to have beneficial effects by reducing hyperammonemia and resulting in improved urea cycle function, which ultimately led to improved motor skills [40].”
BackgroundYu-Taeger, L., El-Ayoubi, A., Qi, P., Danielyan, L., & Nguyen, H. P. (2024) · Cells · doi:10.3390/cells13060469 · Cited by 2
“These observations align with findings in R6/2 HD mice, where reduced lactate clearance, gluco-neogenesis, and urea cycle deficiency have been documented [13,14].”
ResultBasso, M. (2012) · InTech eBooks · doi:10.5772/31579 · Cited by 2
“Of note, CBP regulates the transcription of genes involved in the urea cycle, compromised in the liver of HD patients (Chiang et al., 2007) and this dysfunction contributes to the development of the disease.”
BackgroundManganese and Huntington Disease
Tidball, A. M., Bichell, T. J., & Bowman, A. B. (2014) · Royal Society of Chemistry eBooks · doi:10.1039/9781782622383-00540 · Cited by 2
Nalepa, M., Skweres, A., & Węgrzynowicz, M. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2026.05.285 · Cited by 1
Hogel, M. (2012) · Library and Archives Canada (Government of Canada) · Cited by 1
Metabolic Alterations Amalgamated with Huntington’s Disease
Lakra, P., & Agrawal, N. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_6 · Cited by 1
Bioactive Peptides in Neurodegenerative Diseases
Hassanzadeh, K., Feligioni, M., Zarei, M., Muhialdin, B. J., Maccarone, R., Corbo, M., & Buccarello, L. (2022) · CRC Press eBooks · doi:10.1201/9781003106524-25 · Cited by 1
Papel del factor de transcripción ATF5 en la Enfermedad de Huntington
Hernández, I. H. (2019) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 1
Fasting protects against proteostasis defects induced by hypoxia
Iranon, N. N. (2018) · ResearchWorks at the University of Washington (University of Washington) · Cited by 1
Burg, M., & Jorien, M. (2008) · Lund University Publications (Lund University)
Die Rolle von Mangan bei neurodegenerativen Erkrankungen
Bowman, A. B., Kwakye, G. F., Hernández, E. H., & Aschner, M. (2013) · Perspectives in Medicine · doi:10.1016/j.permed.2011.08.001
Gene–Environment Interactions in Huntington’s Disease
Bichell, T. J., Uhouse, M. A., Bradley, E. M., & Bowman, A. B. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800228-5.00017-0
Kwakye, G. F., & Bowman, A. B. (2009)
Energy metabolism as a target for new treatment strategies in Huntington’s disease
Sjögren, M. (2019) · Lund University Publications (Lund University)
Burke, S. R. A. (2020) · CORE Scholar (Wright State University)
Metabolomics in Autoimmunity, Infections, and Physiological Diseases
Roy, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-39094-4_7
Metadata
- Authors
- Chiang, M.-C., Chen, H.-M., Lee, Y.-H., Chang, H.-H., Wu, Y.-C., Soong, B.-W., Chen, C.-M., Wu, Y.-R., Liu, C.-S., Niu, D.-M., Wu, J.-Y., Chen, Y.-T., & Chern, Y.
- Affiliations
- Institute of Biomedical Sciences, Academia Sinica (TW)
- Chang Gung Memorial Hospital (TW)
- Taipei Veterans General Hospital (TW)
- Changhua Christian Hospital (TW)
- Corresponding author
- Chern, Yijuang
- ORCID
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-01-09
- Volume
- 16
- Issue
- 5
- Pages
- 483-498
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2149248612
- Cited by
- 95
- References
- 68
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 4 · 2023: 6 · 2022: 5 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 2 · 2015: 9 · 2014: 4 · 2013: 5 · 2012: 5
- FWCI
- 1.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Human Molecular Genetics (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- Huntington's disease, mutant huntingtin, C/EBPα, hyperammonemia, citrulline, CREB-binding protein, protein aggregation, low-protein diet, brain-derived neurotrophic factor, striatum, HSP27, HSP70, HSP90, transcriptional regulation, ammonia toxicity
- MeSH terms
- Huntingtin Protein, Animals, Citrulline, Diet, Female, Humans, Huntington Disease, Liver, Male, Middle Aged, Motor Activity, Nerve Tissue Proteins, Nuclear Proteins, Promoter Regions, Genetic, Protein Binding, Urea, Down-Regulation, Disease Progression, Brain-Derived Neurotrophic Factor, Protein Structure, Quaternary, CCAAT-Enhancer-Binding Protein-alpha, Mutant Proteins, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.